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BACKGROUND: Osteosarcoma (OS) is the most common primary bone tumour in children and adolescents. Patients who respond
poorly to chemotherapy have a higher risk of metastatic disease and 5-year survival rates of only 10–20%. Therefore, identifying
molecular targets that are specific for OS, or more specifically, metastatic OS, will be critical to the development of new treatment
strategies to improve patient outcomes.
METHODS: We performed a transcriptomic analysis of chemo-naive OS biopsies and non-malignant bone biopsies to identify
differentially expressed genes specific to OS, which could provide insight into OS biology and chemoresistance.
RESULTS: Statistical analysis of the OS transcriptomes found differential expression of several metallothionein family members, as well
as deregulation of genes involved in antigen presentation. Tumours also exhibited significantly increased expression of ID1 and
profound down-regulation of S100A8, highlighting their potential as therapeutic targets for OS. Finally, we found a significant
correlation between OS and impaired osteoclastogenesis and antigen-presenting activity. The reduced osteoclastogenesis and
antigen-presenting activity were more profound in the chemoresistant OS samples.
CONCLUSION: Our results indicate that OS displays gene signatures consistent with decreased antigen-presenting activity, enhanced
chemoresistance, and impaired osteoclastogenesis. Moreover, these alterations are more pronounced in chemoresistant OS tumour
samples.
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Osteosarcoma (OS) is the most common primary malignant bone
tumour in children and adolescents (Chou and Gorlick, 2006).
Disease progression is marked by aggressive growth, local
recurrence, and poor long-term survival rates because of the
development of fatal pulmonary metastasis in up to 50% of
patients (Wang, 2005). Chemotherapy over many weeks results
in disease-free survival rates of 50–70% for patients with
non-metastatic disease (Bacci et al, 1997; Marina et al, 2004).
However, patients who have a poor response to chemotherapy
have a higher risk of developing pulmonary metastases, which
results in survival rates of o20% (Chou and Gorlick, 2006).
To develop new-targeted therapies to treat OS will require
knowledge of the specific defects associated with non-metastatic
and metastatic disease. Tests to predict whether a patient will
respond to current chemotherapeutics or develop metastases
would enhance our ability to select appropriate treatment
strategies. To this end, a number of studies of OS have generated
gene expression signatures, which have provided insights
into OS biology (Leonard et al, 2003; Baird et al, 2005) and
chemoresistance (Ochi et al, 2004; Man et al, 2005; Mintz et al,
2005). However, these studies have focused on comparisons of
chemosensitive vs chemoresistant, or metastatic vs non-metastatic
disease. Studies comparing non-malignant bone vs OS tissue have
not been earlier reported.
In this study, we compared the transcriptomes of chemo-naive
OS biopsies, collected at the time of diagnosis, with samples of
non-malignant bone. Statistical analysis of the expression profiles
shows that osteosarcomas are characterised by an early deregula-
tion of genes involved in drug resistance, tumour progression,
antigen presentation, and osteoclastogenesis. Furthermore, in
biopsies from patients who developed metastatic disease, these
changes were significantly more pronounced. These data suggest
that patient prognosis is determined early in tumour development
and that enhancing antigen presentation or osteoclastogenesis may
be of clinical value in treating OS.
MATERIALS AND METHODS
Patient samples
Patients presented to the Oncology Clinic at the Princess
Alexandra or at The Wesley Hospitals (Brisbane, Queensland,
Australia). Tumour biopsies were collected at the time of initial
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sdiagnosis, before preoperative chemotherapy, with informed
consent from patients/guardians and with approval from
the relevant institutional Research Ethics Committees. Twenty-
three biopsies were available and subjected to gene expression
profiling analysis. Clinical data detailing response to chemo-
therapy was available for 22 out of 23 patients (Table 1). Patients
were classified as good responders (R) if the tumours had
X90% tumour necrosis, or poor responders (N) if the tumours
had o90% necrosis in response to preoperative chemotherapy
(doxorubicin, 25mgm
–2 and cisplatin, 100mgm
–2) as deter-
mined by histologic examination at the time of definitive surgery
(Salzer-Kuntschik et al, 1983). Non-malignant bone was collected
with consent from five patients presenting for hip or knee
replacement surgery.
Microarray and data analysis
Extraction of RNA from cells and tumours was performed using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Each OS patient
sample was analysed in duplicate using dye swapping. Five non-
malignant bone samples were analysed individually. Labelled
reference RNA and labelled tumour RNA were combined before
hybridisation to Agilent Whole Human Genome Oligo Microarrays
(Agilent Technologies, Santa Clara, CA, USA). Arrays were
scanned on an Agilent DNA Microarray Scanner G2505B (Agilent
Technologies). The microarray data discussed in this work
have been deposited in NCBI’s Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) and are accessible through
GEO series accession number GSE19276. Data extraction was
performed using ImaGene version 6.1 (BioDiscovery Inc, El
Segundo, CA, USA). Statistical analysis of the data was performed
with GeneSpring GX software versions 7.2 and 10.0.1 (Agilent
Technologies). Details of the analysis are described in Supple-
mentary Material.
PCR analysis
For validation, 11 genes were selected at random from the 20 most
highly differentially expressed molecules between non-malignant
bone and OS. For PCR, 2mg of non-malignant bone or OS tumour
biopsy RNA was reverse transcribed with BioScript (Bioline,
Sydney, Australia); PCR was performed using Taq DNA poly-
merase with ThermoPol II buffer (New England Biolabs, Ipswich,
MA, USA) at an annealing temperature of 53–551C for 30 cycles on
a ThermoHybaid PxE0.2 (Thermo Scientific, Waltham, MA, USA).
Primers were as follows: ID1 (forward 50-CGGATCTGAGGGA
GAACAAG-30 and reverse 50-CTGAGAAGCACCAAACGTGA-30),
PRDX4 (forward 50-GAGGACTTGGGCCAATAAGG-30 and reverse
50-TTCACTACCAGGTTTCCAGC-30), TPM2 (forward 50-CGAGAG
TAAATGTGGGGACC-30 and reverse 50-TAAAGGATGAAGCCA
GTGCC-30), MT1E (forward 50-TGCTTGTTCGTCTCACTGG-30
and reverse 50-AAAGAAATGCAGCAAATGGC-30), FKBP9 (forward
50-TACCTGAAAACTGTGAGCGG-30 and reverse 50-GTTCATCT
GGTTTGGCTTCC-30), S100A13 (forward 50-ACCTTATGACCTGT
CAGCCC-30 and reverse 50-CCGAGTCCTGATTCACATCC-30),
S100A8 (forward 50-TGGGCATCATGTTGACCGAGCTG-30 and reverse
50-GCCACGCCCATCTTTATCACCAGA-30), CTSG (forward 50-CG
CATCTTCGGTTCCTACG-30 and reverse 50-GCTTCTCATTGTT
GTCCTTATCC-30), VWA5B2 (forward 50-TACTCGGGAGCTAC
TCTTCC-30 and reverse 50-CATATGGCTGTGTCAGAGGG-30),
AZU1 (forward 50-AGCATCAGGTCGTTCAGGTT-30 and reverse
50-CAGAATCAAGGCAGGCACTTC-30), PFC (forward 50-GCTCT
GTCACCTGCTCCAA-30 and reverse 50-GCGGCTTCGTGTCTC
CTTA-30).
RESULTS
Gene expression profiling of OS vs non-malignant bone
We compared gene expression in 23 OS biopsies and 5 non-
malignant bone samples. Our analysis yielded a suite of 305
differentially expressed genes (two-fold or greater, Po0.05)
between OS and non-malignant bone, of which 206 were annotated
(Supplementary Table 1). Table 2 lists the 10 most highly up and
10 most highly downregulated genes, 11 of which were selected at
random and their differential expression confirmed by PCR in two
non-malignant bone samples and in five randomly selected OS
tumour biopsies (Figure 1). Of the 36 upregulated genes, 47%
were associated with cellular growth and proliferation (e.g. ID1,
ANXA2, BTG3, MT2A, ITGB1, NDUFAF2). The most well-
represented family of genes within this group was the metallothio-
nein family, linked to intrinsic and acquired drug resistance
(Cherian et al, 2003). Seven members of this family, MT1E, MT1H,
MT1X, MT2A, MT1B, MT1G, and MT1L, were upregulated in
our OS samples, and three were among the 10 most highly
upregulated genes (Table 2). The inhibitor of DNA binding 1, ID1
(þ4.07, P¼0.003), peroxiredoxin 4, PRDX4 (þ3.63, P¼0.007),
S100 calcium-binding protein A13, S100A13 (þ2.66, P¼0.009),
annexin 2, ANXA2 (þ2.62, P¼0.003), and destrin, DSTN (þ2.50,
P¼0.001), earlier reported as positive regulators of angiogenesis,
tumour progression and invasion (Fong et al, 2003; Landriscina
et al, 2006; Estornes et al, 2007; Lee et al, 2008; Mussunoor and
Murray, 2008; Iwatsuki et al, 2009) were all induced in OS samples
(Table 2).
Analysis of the 170 downregulated genes found a large number
associated with the inflammatory (26%) and cell-mediated (31%)
immune response, as well as with antigen presentation (24%).
Ingenuity pathway analysis (IPA) (Ingenuity Systems, Mountain
View, California, USA) identified the antigen-presentation pathway
as downregulated in OS with HLA-C, HLA-DOA, HLA-DPB1,
HLA-DPA1, and HLA-E all expressed 2.17- to 3.45-fold lower
in the lesions than in non-malignant bone (P¼0.002–0.04).
However, the most highly differentially expressed gene was
Table 1 Clinical information for the osteosarcoma patients used in
the study
Tumour
ID
Age
(years) Gender
Site of
tumour
Tumour
necrosis (%) Response
G3 15 M Proximal tibia 100 R
S4 29 F Sacrum o5N
S5 27 F Proximal humerus o50 N
S7 39 M Pelvis o50 N
M8 24 F Distal femur 25 N
L9 17 M Tibia 75 N
W10 14 M Distal femur 75 N
A13 7 F Proximal tibia 80 N
M14 67 M Pelvis 75 N
S15 76 F Tibia o90 N
W16 15 F Proximal Humerus o90 N
O17 12 M Distal femur 75 N
M18 18 M 8th rib 98 R
K19 17 M Proximal tibia 50 N
E20 13 F Femur 95 R
M21 15 M Distal femur 95 R
W22 15 F Femur 80 N
G23 18 M Distal femur 80 N
F2BR 18 M Proximal tibia 80 N
A3BR 19 F Distal femur 80 N
V4BR 16 M Calcaneum o5N
M7BR 14 F Distal femur 492 R
T1
a 37 F Proximal tibia U U
Response to chemotherapy: R¼good response; N¼poor response; U¼unknown.
aThis patient was used in the comparison between osteosarcoma and non-malignant
bone, but not in the chemotherapy response study.
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sthe S100 calcium-binding protein A8 (S100A8), a marker of
a number of inflammatory conditions (Zreiqat et al, 2007), which
was downregulated 100-fold in OS (P¼0.005) (Table 2). Also
downregulated were cathepsin G (CTSG;  16.67, P¼0.02) and
azurocidin 1 (AZU1;  6.67, P¼0.05), which regulate monocyte/
macrophage function and chemotaxis in inflammatory conditions
(Pereira, 1995; Miyata et al, 2007).
The OS biopsies also revealed a transcriptomic signature
characteristic of reduced osteoclastogenesis. ID1 is an inhibitor
of osteoclast differentiation (Lee et al, 2006) and was induced four-
fold in OS biopsies. Similarly, there was a 100-fold down-
regulation of S100A8, which is highly expressed in osteoclasts
(Zreiqat et al, 2007), and significantly lower expression of another
13 genes associated with negative regulation of osteoclast
differentiation/function, or indicating diminished osteoclast pre-
sence or activity. These genes included von Willebrand factor A
domain, 5B2 (VWA5B2;  11.11, P¼0.02), FGR, a member of the
Src family of protein tyrosine kinases ( 5.56, P¼0.02), TYRO
protein kinase-binding protein (TYROBP;  5.26, P¼0.04), the
Rac small GTPase RAC2 ( 4.76, P¼0.01), RelA/p65 ( 4.55,
P¼0.005), MYC ( 3.70, P¼2.77 10
 16), signal regulatory
protein a (SIRPa/SIRPA;  2.94, P¼0.006), tartrate-resistant acid
phosphatase (ACP5/TRAP,  2.86, P¼0.005), BCL2 ( 2.5-fold,
P¼0.005), high-mobility group box 1 (HMGB1;  2.33, P¼0.002),
V-ATPase (ATP6V0D1;  2.27, P¼0.04), leukotriene B4 receptor
(LTB4R;  2.22, P¼0.03), and gelsolin (GSN,  2.08, P¼0.04). To
see whether the reduction in ACP5/TRAP gene expression
correlated with a decrease in the number of osteoclasts in OS,
we performed immunohistochemistry on FFPE sections of OS
biopsies and of non-malignant bone with a monoclonal antibody
to ACP5/TRAP. We found a 2.5-fold decrease in the number of
osteoclasts in OS biopsies compared with non-malignant bone,
which correlated with the observed 2.3-fold decrease in ACP5/
TRAP gene expression (Figure 2A). Furthermore, the decrease in
ACP5/TRAP expression was significantly more marked in the
biopsies of patients, which showed a poor response to chemo-
therapy treatment than in those who exhibited a good response
(Figure 2B), suggesting that a reduction in osteoclastogenesis
is not only associated with OS in general, but also with
chemoresistance.
Gene expression profiling of good responders vs poor
responders
Osteosarcomas are inherently drug-resistant tumours (Chou and
Gorlick, 2006), and, therefore, the most commonly used predictor
of disease outcome is a patient’s initial response to chemotherapy.
Unfortunately, this response cannot be assessed at the time of
presentation. To specifically search for genes that could be
predictive of chemotherapeutic response and drug resistance at
the time of diagnosis, patients were divided into good (n¼5) and
poor (n¼17) responders using the criteria already described. A set
of 123 genes was found to be significantly differentially expressed
(Po0.05) between the two groups, of which 61 were annotated
(Table 3). Most of these genes (94%) were upregulated in the good
responders and were associated with cellular development, growth,
and proliferation, suggesting that good responders may have
tumours that are more proliferative and may, therefore, be more
sensitive to the effects of chemotherapy. Among the most highly
Table 2 Osteosarcoma vs non-malignant bone
Probe ID Symbol Description and accession number Fold change P-value
A_23_P252306 ID1 Inhibitor of DNA binding 1, dominant-negative
helix-loop-helix protein [NM_002165]
4.07 0.00276
A_23_P114232 PRDX4 Peroxiredoxin 4 [NM_006406] 3.63 0.00664
A_23_P216501 TPM2 Tropomyosin 2 (b) [NM_213674] 3.30 0.00237
A_23_P206724 MT1E Metallothionein 1E [NM_175617] 3.11 0.00661
A_23_P334709 FKBP9 FK506-binding protein 9, 63kDa [NM_007270] 3.08 0.0111
A_23_P163782 MT1H Metallothionein 1H [NM_005951] 3.02 0.0169
A_24_P125096 MT1X Metallothionein 1X [NM_005952] 2.72 0.0316
A_23_P372874 S100A13 S100 calcium-binding protein A13 [NM_005979] 2.66 0.00955
A_32_P94798 ANXA2 Annexin A2 [NM_001002857] 2.62 0.00359
A_23_P408095 DSTN Destrin (actin depolymerising factor) [NM_001011546] 2.50 0.00140
A_23_P434809 S100A8 S100 calcium-binding protein A8 (calgranulin A) [NM_002964]  100.00 0.00549
A_23_P37856 HBA1 Homo sapiens haemoglobin, a 1 (HBA1), mRNA [NM_000558]  50.00 4.26E 10
A_23_P140384 CTSG Cathepsin G [NM_001911]  16.67 0.0222
A_23_P80867 VWA5B2 von Willebrand factor A domain containing 5B2 [AL834499]  11.11 0.0222
A_23_P153741 AZU1 Azurocidin 1 (cationic antimicrobial protein 37) [NM_001700]  6.67 0.0485
A_23_P22444 CFP Properdin P factor, complement [NM_002621]  6.25 0.0496
A_23_P208866 GMFG Glia maturation factor, g [NM_004877]  5.88 0.00748
A_24_P207195 IRX3 Iroquois homeobox protein 3 [NM_024336]  5.88 0.00263
A_23_P403886 GLYAT Glycine-N-acyltransferase [NM_005838]  5.56 0.00391
A_23_P156708 TNXB Tenascin XB [NM_019105]  5.56 0.00351
Top 10 upregulated and 10 downregulated genes between osteosarcoma biopsies and non-malignant bone samples.
123 45 67
-Actin
ID1
PRDX4
TPM2
MT1E
S100A13
FKBP9
S100A8
CTSG
VWA5B2
AZU1
PFC
NB                              Osteosarcoma
Upregulated
Downregulated
Figure 1 Validation of highly differentially expressed genes in osteo-
sarcoma vs non-malignant bone. Eleven genes were selected at random
from Table 1 and validated by PCR in two non-malignant bone samples
(lanes 1 and 2), and five randomly selected osteosarcoma patients (lanes
3–7). The results are shown in groups of genes upregulated and
downregulated in osteosarcoma compared with non-malignant bone.
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supregulated genes in good responders was thymosin b 10 (TSMB10,
þ5.34-fold, P¼0.017), which had been identified within the suite of
differentially expressed genes between good and poor responders in an
earlier study of OS tumour biopsies (Ochi et al, 2004).
To test the suitability of this set of 123 genes to separate between
good and poor responders, we performed unsupervised hierarch-
ical clustering of the data. With the exception of one patient (M18),
the gene set was able to clearly separate 21 out of 22 (495%) OS
patients on the basis of their response to chemotherapy (Figure 3).
We examined the possibility that some of these genes could serve
as individual predictors of chemotherapeutic response. We
selected individual genes from the list based on their Xthree-
fold expression (Table 3), and looked at their levels of expression
in individual patients. Of the selected genes, only TMSB10, SPP1,
CTSB, TYROBP/DAP12, and IFI30 showed significant (Po0.05)
differential expression between patients in the two groups, with
IFI30 (P¼0.0005) showing the most significant difference (Figure 4).
One of the major obstacles to effective treatment of OS patients
is intrinsic or acquired resistance to the cytotoxic effects of
anticancer agents. The mechanism dictating this resistance in OS is
still unknown, but may involve a number of gene families, which
mediate detoxification, increased efflux from the cell, and
increased DNA repair (Chou and Gorlick, 2006). Therefore,
understanding the mechanism of drug resistance and identifying
genes that are involved may lead to new therapies that could
improve survival. The cytochrome P450 family of enzymes
functions in the detoxification of anticancer drugs (Simpson,
1997). As our signature found CYP4X1 differentially expressed
between good and poor responders, we looked at the mRNA
expression levels in each patient of CYP4X1 and other cytochrome
P450 family members (Figure 5F). Of the 50 or more P450 genes
present on the array, only 19 had detectable expression levels in
our tumour biopsies, and of these, only CYP4X1 had significant
differential expression associated with chemotherapeutic response.
However, given that CYP4X1 is an orphan P450 protein with no
assigned biological function (Stark et al, 2008), and that it was
downregulated in good responders, its function in OS drug
response remains unclear.
Other enzyme families responsible for resistance to many
chemotherapeutic agents include the glutathione-S-transferases
(GSTs) (Ekhart et al, 2009) and the ATP-binding cassette (ABC)
transporters (Sharom, 2008). We, therefore, compared the expres-
sion of GST and ABC family members between good and poor
responders. Only five GSTs were expressed in our samples, but
none significantly (Figure 5A). Similarly, only one ABC transpor-
ter, ABCG2, was found expressed in our samples, but its levels were
not significantly different between the two groups (Figure 5C).
Moreover, we found no significant difference in the expression of
other genes involved in DNA damage response, drug metabolism,
apoptosis, or survival (Figures 5B, D and E). Taken together, our
data indicate that genes classically associated with multi-drug
resistance do not correlate with chemotherapeutic response in OS.
DISCUSSION
Despite intensive multi-agent chemotherapy, OS remains an
aggressive, highly metastatic, and relatively drug-resistant tumour
with poor long-term survival rates (Chou and Gorlick, 2006). The
mechanisms behind metastasis and chemoresistance in OS are not
well understood, but are likely to be due to the innate biology of
metastatic and chemoresistant lesions (Gorlick and Meyers, 2003).
Therefore, understanding the basic tumour biology is central to
understanding OS pathogenesis and chemoresistance. In this
study, we used chemo-naive OS biopsies and, for the first time,
compared their transcriptomes to those of non-malignant bone.
We identified a unique gene signature showing increased
expression of genes associated with tumour progression and drug
resistance, and decreased expression of genes associated with
antigen presentation and osteoclastogenesis in all OS lesions. In
addition, tumours that were chemoresistant were characterised by
more pronounced inhibition of osteoclastogenesis markers and
antigen-presenting activity than tumours that were chemosensi-
tive. We noted no significant difference in the expression of genes
classically associated with drug resistance between chemosensitive
and chemoresistant tumours.
This study identified ID1 as a potentially important molecule in
the regulation of many of the characteristics of OS. Increased
expression of ID1 in the OS biopsies has been shown to be
involved in the proliferation, survival, angiogenesis, metastasis
(Ling et al, 2006), and formation of a permissive metastatic niche
in other cancer types (Lyden et al, 1999), and may be similarly
involved in OS. Recently, ID1 has been identified as a novel
inhibitor of PTEN and p53, leading to AKT-dependent activation
of the canonical Wnt-signalling pathway (Lee et al, 2009). The
Wnt-signalling pathway has earlier been shown to be important to
the regulation of OS progression (Hoang et al, 2004; Geryk-Hall
and Hughes, 2009; Kansara et al, 2009). Thus, there is evidence that
the overexpression of ID1 in OS may be causally involved in the
growth, survival, and metastatic behaviour of OS. If true, then
targeting of the Akt and Wnt pathways could be of value in OS
(Geryk-Hall and Hughes, 2009).
Mintz et al (2005) earlier reported that genes involved in
osteoclast differentiation and function in OS were mostly
associated with a poor chemotherapeutic response. We now report
that osteoclast numbers are decreased in all OS lesions. Thus, the
loss of osteoclasts in OS may be involved in OS metastasis,
although the mechanism by which OS induce osteoclast loss is
unknown. An earlier transcriptomic study in seven OS biopsies
(Patino-Garcia et al, 2009) showed up-regulation of EBF2, a known
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Figure 2 Impaired osteoclastogenesis in osteosarcoma correlates with chemoresistance. (A) Osteoclast number is expressed as the average number of
osteoclasts per  20 field in immunohistochemically stained FFPE sections from osteosarcoma biopsies (OS) and non-malignant bone (NB). The ACP5
expression as measured by microarray analysis and expressed as normalised intensity. ***Po0.0001, *P¼0.0491. Bars: meanþs.e.m. (B) ACP5 expression
in good and poor responders, as measured by microarray analysis and expressed as normalised intensity. *P¼0.0428. Bars: meanþs.e.m.
Transcriptomicstudy of osteosarcoma and normal bone
L Endo-Munoz et al
76
British Journal of Cancer (2010) 103(1), 73–81 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sTable 3 Good response vs poor response
Genbank Synonym Common name Fold change P-value
NM_021103 TMSB10 Thymosin, b 10 5.34 0.0171
NM_000582 SPP1 Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I,
early T-lymphocyte activation 1)
4.82 0.0171
NM_006332 IFI30 Interferon, g-inducible protein 30 4.36 0.0224
NM_002952 RPS2 Ribosomal protein S2 3.70 0.0487
NM_005514 HLA-B Major histocompatibility complex, class I, B 3.56 0.0487
NM_000455 STK11 Serine/threonine kinase 11 (Peutz–Jeghers syndrome) 3.49 0.0249
NM_147780 CTSB Cathepsin B 3.48 0.0355
NM_153461 IL17RC Interleukin 17 receptor C 3.39 0.0415
NM_002032 FTH1 Ferritin, heavy polypeptide 1 3.32 0.0355
NM_005507 CFL1 Cofilin 1 (non-muscle) 3.29 0.0251
NM_002116 HLA-A Major histocompatibility complex, class I, A 3.17 0.0379
NM_003332 TYROBP TYRO protein tyrosine kinase-binding protein 3.16 0.0487
NM_001022 RPS19 Ribosomal protein S19 3.16 0.023
NM_053275 RPLP0 Ribosomal protein, large, P0 3.14 0.0439
NM_000992 RPL29 Ribosomal protein L29 a.k.a. heparin/eparan sulphate
interacting protein (HIP)
3.11 0.0497
NM_002117 HLA-C Major histocompatibility complex, class I, C 2.99 0.0401
NR_002205 FTHL12 Ferritin, heavy polypeptide-like 12 2.95 0.0392
NM_001404 EEF1G Eukaryotic translation elongation factor 1 g 2.93 0.0443
NM_001014 RPS10 Ribosomal protein S10 2.83 0.0171
NM_001003 RPLP1 Ribosomal protein, large, P1 2.81 0.0397
NM_003295 TPT1 Tumour protein, translationally controlled 1 2.66 0.0365
BC031631 CFLP1 Cofilin pseudogene 1 2.65 0.0232
NM_006435 IFITM2 Interferon induced transmembrane protein 2 (1-8D) 2.61 0.0489
NM_002948 RPL15 Ribosomal protein L15 2.60 0.0497
NM_001020 RPS16 Ribosomal protein S16 2.58 0.0355
NM_000982 RPL21 Ribosomal protein L21 2.56 0.0489
NM_178230 COAS2 Cyclophilin-LC 2.51 0.0444
NM_000979 RPL18 Ribosomal protein L18 2.50 0.0455
NM_001022 RPS19 Ribosomal protein S19 2.47 0.0392
NM_003295 TPT1 Tumour protein, translationally controlled 1 2.47 0.0439
BC034271 FANCC Fanconi anaemia, complementation group C 2.45 0.0214
NM_001997 FAU Finkel–Biskis–Reilly murine sarcoma virus (FBR-MuSV)
ubiquitously expressed (fox derived); RPS30
2.45 0.043
NM_001006 RPS3A Ribosomal protein S3A 2.45 0.0497
AY358369 SIGLEC5 Sialic acid-binding Ig-like lectin 5 (CD170) 2.45 0.0489
NM_181468 ITGB4BP Integrin b 4-binding protein 2.40 0.0444
NM_000990 RPL27A Ribosomal protein L27a 2.39 0.0392
NM_002489 NDUFA4 NADH dehydrogenase (ubiquinone) 1 a subcomplex, 4, 9kDa 2.32 0.0439
AK098605 FMN2 Formin 2 2.32 0.0443
NM_001019 RPS15A Ribosomal protein S15a 2.32 0.0401
NM_002107 H3F3A H3 histone, family 3A 2.30 0.0303
NM_005620 S100A11 S100 calcium-binding protein A11 (calgizzarin) 2.30 0.0487
NM_006013 RPL10 Ribosomal protein L10 2.28 0.0489
NM_005009 NME4 Non-metastatic cells 4, protein expressed in 2.27 0.0365
NM_006886 ATP5E ATP synthase, H+ transporting, mitochondrial F1 complex,
a ˚ subunit
2.23 0.0171
NM_001008741 LOC388817 Peptidylprolyl isomerase A-like 2.23 0.0444
NM_032828 ZNF587 Zinc-finger protein 587 2.22 0.0487
NM_015933 HSPC016 Hypothetical protein HSPC016 2.22 0.0258
NM_024040 CUEDC2 CUE domain containing 2 2.19 0.0214
NM_006808 SEC61B Sec61 b subunit 2.18 0.0465
NM_002406 MGAT1 Mannosyl (a-1,3-)-glycoprotein
b-1,2-N-acetylglucosaminyltransferase
2.14 0.0415
NM_002797 PSMB5 Proteasome (prosome, macropain) subunit, b type, 5 2.13 0.0171
NM_001021 RPS17 Ribosomal protein S17 2.10 0.0489
NM_000182 HADHA Hydroxyacyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A
thiolase/enoyl-coenzyme A hydratase (trifunctional protein),
a subunit
2.07 0.0392
NM_012067 AKR7A3 Aldo-keto reductase family 7, member A3
(aflatoxin aldehyde reductase)
2.06 0.0224
XM_376787 RPS26P10 Ribosomal protein S26 pseudogene 10 2.06 0.043
NM_005340 HINT1 Histidine triad nucleotide-binding protein 1 2.04 0.0444
NM_145893 A2BP1 Ataxin 2-binding protein 1  2.44 0.0357
NM_015503 SH2B1 SH2-B adaptor protein  2.33 0.0487
NM_178033 CYP4X1 Cytochrome P450, family 4, subfamily X, polypeptide 1  2.08 0.0487
NM_003893 LDB1 LIM domain-binding 1  2.04 0.0355
CR749256 XRCC2 X-ray repair complementing defective repair in Chinese hamster cells 2  2.00 0.0357
Genes differentially expressed between biopsies of good responders and poor responders. The list shows 61 annotated genes from the original list of 123 genes.
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stranscription factor for osteoprotegerin (OPG), a major negative
regulator of osteoclastogenesis (Khosla, 2001). In contrast, our
study identified the up-regulation of ID1 in OS. As ID1 is a
negative regulator of osteoclast differentiation (Lee et al, 2006), it
is possible that the overexpression of ID1 in OS lesions may
provide an explanation for OS-induced osteoclast loss. Our
microarray analysis of primary OS lesions also indicates that
S100A8 was profoundly reduced in OS lesions (P¼0.005; fold
decrease¼100). S100A8 is highly expressed in osteoclasts in which
it functions as a chemotactic-signalling molecule involved in the
coupling of osteoclast and osteoblast activity (Zreiqat et al, 2007).
In addition, decreased expression of 15 other genes involved in
osteoclast development and function (Pereira et al, 1990; Garcia
et al, 1996; Lowell et al, 1996; Chertov et al, 1997; Chellaiah et al,
2000; Duong et al, 2000; Battaglino et al, 2002; Lundberg et al,
2007; Shahbazi et al, 2007; Kawano et al, 2008; Zhou et al, 2008;
Soehnlein and Lindbom, 2009) was observed in the OS biopsies.
Among these was CTSG, which is necessary for the recruitment of
osteoclast precursors (Wilson et al, 2009b) and for the activation
of MMP9, which in turn activates TGFb to enhance osteoclast
activity (Wilson et al, 2009a); TYROBP/DAP12, which is essential
for RANK signalling and osteoclast multinucleation and differ-
entiation (Humphrey et al, 2004; Mocsai et al, 2004), and the NFkB
subunit, RelA/p65, which promotes osteoclastogenesis by inhibit-
ing JNK-mediated osteoclast apoptosis (Vaira et al, 2008; Soysa
and Alles, 2009). We also observed decreased expression of
osteoclast cellular components such as ACP5/TRAP, a classic
marker of mature and active osteoclasts (Hayman, 2008) and
ATP6V0D1, which is found in the osteoclast membrane and critical
for its resorptive activity (Xu et al, 2007). Furthermore, the
decreased expression of osteoclast cellular components correlated
with a decrease in the number of osteoclast cell counts in
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Figure 3 Unsupervised clustering of 123 differentially expressed genes
between good responders and poor responders. Genes were selected
based on normalised data values that were greater or less in 5 good
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Level of expression – lowest (light green), highest (bright red).
G
e
n
e
 
e
x
p
r
e
s
s
i
o
n
(
n
o
r
m
a
l
i
z
e
d
 
i
n
t
e
n
s
i
t
y
)
G
e
n
e
 
e
x
p
r
e
s
s
i
o
n
(
n
o
r
m
a
l
i
z
e
d
 
i
n
t
e
n
s
i
t
y
)
G
e
n
e
 
e
x
p
r
e
s
s
i
o
n
(
n
o
r
m
a
l
i
z
e
d
 
i
n
t
e
n
s
i
t
y
)
G
e
n
e
 
e
x
p
r
e
s
s
i
o
n
(
n
o
r
m
a
l
i
z
e
d
 
i
n
t
e
n
s
i
t
y
)
G
e
n
e
 
e
x
p
r
e
s
s
i
o
n
(
n
o
r
m
a
l
i
z
e
d
 
i
n
t
e
n
s
i
t
y
)
2.0 5
3
4
2
1
0
3
4
2
1
0
4
6
2
0
25
15
20
10
5
0
Good Poor
Good Poor Good Poor
Good Poor
Good Poor
1.5
1.0
0.5 P = 0.003
P = 0.037
P = 0.0021
TMSB10
SPP1 CTSB
TYROBP
IFI30
P = 0.0005
P = 0.004
0.0
Figure 4 Expression of highly differentially expressed genes between good and poor responders. Expression, measured as normalised spot intensity, in
each of the 5 good responders and 17 poor responders of 6 highly differentially expressed genes between the two groups. P-value (ANOVA, Welch T-test,
Benjamini and Hochberg false discovery rate). Bars: s.e.m.
Transcriptomicstudy of osteosarcoma and normal bone
L Endo-Munoz et al
78
British Journal of Cancer (2010) 103(1), 73–81 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
simmunohistochemically stained sections of OS compared with
non-malignant bone. Thus, we provide evidence that OS lesions
are associated with a reduction in osteoclasts.
The down-regulation of osteoclast differentiation in OS was
accompanied by down-regulation of five MHC Class I and II genes
belonging to the antigen-presentation pathway and of HMGB1.
The correlation between MHC Class I and II deficiencies in human
tumours and metastatic potential/reduced survival rates in patients
is well documented (Meissner et al, 2005; Chamuleau et al, 2006;
Ramnath et al, 2006; Seliger, 2008), whereas the interaction of
HMGB1 with Toll-like receptor 4 on dendritic cells has been shown
to be essential for tumour antigen processing and presentation
(Apetoh et al, 2007). Interestingly, we observed a significant
increase in the expression of five genes with overlapping functions
in antigen presentation and osteoclastogenesis in the good responder
group – IFI30 (P¼0.0005), TYROBP/DAP12 (P¼0.002), TMSB10
(P¼0.003), CTSB (P¼0.004), and SPP1 (P¼0.037). The IFI30
expression, in melanoma (Goldstein et al, 2008) and squamous cell
carcinoma (Wenzel et al, 2008), has been shown to enhance antigen
presentation and to activate CTSB (Goldstein et al, 2008), which is
required for osteoclast fusion during differentiation (McMichael
et al, 2009). In addition, TYROBP/DAP12 is associated with active
innate immune responses (Lanier, 2009) and, together with SPP1,
also has a crucial function in osteoclast differentiation (Humphrey
et al, 2004; Mocsai et al, 2004; Dalla-Torre et al,2 0 0 6 ;I n u iet al,
2009). Furthermore, the expression of SPP1 in OS lesions has been
correlated with improved overall survival (Dalla-Torre et al, 2006).
Although there is some evidence connecting TMSB10 expression to
carcinogenesis (Lee et al, 2001; Sardi et al, 2002; Alldinger et al,
2005), this is the first report linking TMSB10 expression to good
chemotherapeutic response in OS. In addition, good responders had
significantly higher levels of ACP5/TRAP gene expression than poor
responders. Thus, these results are the first to show a possible
association between antigen presentation and osteoclastogenesis
in the biology of OS tumours and in their chemotherapeutic
response.
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sensitivity. First, we found that OS displayed a gene signature that was
consistent with a chemoresistant phenotype. Second, genes associated
with classical drug resistance were not overrepresented in chemoresis-
tant OS lesions. These conclusions are supported by the increased
expression of seven metallothionein family members in the OS biopsies.
The function of metallothioneins in drug resistance has been well
documented (Cherian et al, 2003; Theocharis et al, 2004; Surowiak et al,
2007), and an earlier transcriptomic study of OS reported up-regulation
of MTIG and MT1L in poorly responsive tumours (Mintz et al, 2005).
In this study, we found no correlation between their level of expression
and response, a finding that is supported by others (Uozaki et al, 1997;
Shnyder et al, 1998). Moreover, we found no correlation between good
and poor responses and the expression of molecules classically
associated with chemoresistance, such as GSTs and ABC transporters,
or DNA damage response, apoptosis, drug metabolism, and survival
genes. These results suggest that drug resistance may be a global
characteristic of all osteosarcomas and that drug resistance, in
chemoresistant lesions, is likely to be mediated by novel pathways.
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